Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
| Price | $7.08 |
|---|---|
| Market cap | $14.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 3.25-41.8 |
| Beta | 1.66 |
Explore QNRX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.